Objective The aim of this study was to quantify glycosaminoglycans (GAGs) in amniotic fluid (AF) from an MPS VII fetus compared with age-matched fetuses obtained from normal pregnancies.
INTRODUCTION
Mucopolysaccharidosis VII (MPS VII; Sly syndrome) (OMIM #253220) is an autosomal recessive lysosomal storage disorder (LSD) caused by a deficiency of β-glucuronidase (GUSB). This enzyme deficiency leads to accumulation of chondroitin sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS). 1 The first MPS VII case was described in 1973 by Dr. William S. Sly.
2
Patients with MPS VII have a broad range of clinical signs and symptoms including coarse facies, skeletal dysplasia, short stature, hernias, hepatosplenomegaly, neurological impairment, and corneal clouding. The clinical spectrum ranges from a severe form with lethal hydrops fetalis to attenuated forms with survival into adulthood despite physical and cognitive impairment. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] GUSB is localized to chromosome 7q21.11, and the 21 kb gene contains 12 exons. [13] [14] [15] [16] Several groups have independently reported many mutations within GUSB that result in different MPS VII phenotypes. 10, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Sixty-three mutations have been described according to the Human Gene Mutation database as of November 2016. The incidence of MPS VII is not well documented, and many cases are not diagnosed due to spontaneous abortion. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Clinical manifestations of MPS usually do not appear at birth; however, accumulation of glycosaminoglycans (GAGs) has been reported histopathologically in the human fetus (MPS I, II, III, IVA) and placenta (MPS II, VI), [43] [44] [45] indicating that the disease process starts and can be detected prior to appearance of clinical signs and symptoms. Prenatal studies for MPS VII have been performed primarily to measure GUSB deficiency and for histophatologic analysis. 8, [46] [47] [48] [49] [50] [51] [52] [53] Until now, no study has reported on the quantification of GAGs in fetal specimens with MPS VII. The aim of this study was to quantify GAGs in amniotic fluid (AF) from an MPS VII fetus and to compare with age-matched AF obtained from normal pregnancies.
METHODS

Tandem mass spectrometry
Chondroitin-4-sulfate (C4S), chondroitin-6-sulfate (C6S), dermatan sulfate (DS), heparan sulfate (HS-0S, NS and diS 1 ), and keratan sulfate (KS) (mono-KS and di-KS) were measured in AF by liquid chromatography tandem mass spectrometry and compared with AF of five age-matched controls corrected by protein.
Ten microliters of AF was added to a 96-well Omega 10 K filter plate (Pall Co, MI) with 90 μL of 50 mM Tris HCL (pH 7.0) with a 96-well receiver plate at the bottom. Samples were incubated with a mixture of internal standard (chondrosine), chondroitinase (B, ABC, and ACII), heparitinase, and keratanase II (Seikagaku Co, Japan) according to the same method described by Kubaski et al. digested by heparitinase. Keratan sulfate was measured by Gal(6S)β1 → 4GlcNAc(6S) (di-KS) and Galβ1 → 4GlcNAc(6S) (mono-KS) digested by keratanase II.
Specific precursor ion and its product, m/z, and liquid chromatography were used to quantify each disaccharide, respectively (354. 3, 193 This study was approved by the ethics committee of Hospital de Clínicas de Porto Alegre (project # 03066), and informed consent was obtained from the parents for prenatal diagnosis and molecular analysis.
RESULTS
The proband was a female fetus from non-consanguineous parents that presented with hydrops fetalis at 19 weeks of pregnancy and spontaneously died at 25 weeks of pregnancy. The mother, 31-year-old, had three previous pregnancies (one stillbirth and two children that died in the first year of life). No investigation was performed on these previous siblings.
Because the most common causes of non-immune hydrops fetalis, as congenital infection, malformations, and chromosomal abnormalities, were ruled out, a LSD was suspected. Thus, the levels of GAGs in AF at 21 weeks of pregnancy were measured using tandem mass spectrometry.
We observed that the concentration of GAGs found within the patient's AF was greatly elevated (≥10 SD) when compared to age-matched controls ( Table 1) .
Levels of DS, HS, and C6S were at least tenfold higher in MPS VII than those in the age-matched controls, and C4S and KS were over threefold higher. C4S, C6S, HS-0S, and HS-NS were elevated as primary storage materials. Levels of mono-sulfated and di-sulfated KS were also elevated, secondarily. HS-diS1 level was not elevated (Table 1) . Due to the elevated levels of DS, HS, and C6S, a diagnosis of MPS VII was suspected.
Biochemical analysis showed the very low enzymatic activity of GUSB in cultured amniocytes and AF, confirming the initial suspicion. The moderately low activity of β-galactosidase and a slight reduction in the activity of neuraminidase were also observed, but these alterations were not considered clinically relevant (Table 2) . α-Mannosidase and total hexosaminidase were evaluated in AF supernatant to exclude mucolipidosis II/III. 55 
Molecular analysis
Molecular analyses were conducted by next generation sequencing with a customized panel including the GUSB gene. A total of 36 000 reads were obtained with 1500 reads per amplicon. The Asn379Asp (p.N379D) (c.1135A > G) alteration was found in a homozygous state for the affected fetus and in a heterozygous state in both parents. This is the first report of p.N379D substitution in GUSB. Asn379 is conserved in GUSB in 50 species including humans, mice, and Escherichia coli, and is a buried residue. 56 Consequently, alteration of the neutral Asn to acidic Asp is likely to disrupt the structure of the protein. The PredicSNP 2 program indicates that this change is likely deleterious to the protein structure. 57 More molecular studies are needed to confirm the function of Asn379 in the structure or function of GUSB.
DISCUSSION
We have demonstrated that AF surrounding a fetus with MPS VII at 21 weeks of gestational age has a marked elevation of GAGs, including secondary storage of KS, indicating that AF is valuable for measuring GAG level to detect MPS before birth. In 1993, Chabás et al. described the use of chorionic villus (CVS) and AF to measure GUSB activity for prenatal diagnosis. 48 Reduced levels of GUSB activity have subsequently been detected in these tissues for several MPS VII fetuses. [49] [50] [51] [52] Groener et al. used two-dimensional electrophoresis to demonstrate elevated DS and CS in fetal blood in a confirmed MPS VII fetus. 53 However, no prior study has been reported on quantification of the levels of GAGs in CVS or AF. Our study shows that all GAGs and their subclasses, except for HS-diS1, are noticeably elevated in AF of the affected fetus compared with those in the age-matched controls and that the biochemical finding of GAGs is matched with the previous pathological findings of GAG accumulation in the affected fetuses as described above. [43] [44] [45] We and others have shown that KS is secondarily elevated in plasma (serum) and urine in several types of MPS and LSDs (in addition to MPS IV in which the deficient enzyme is directly involved in the catabolism of KS). [58] [59] [60] We previously proposed that secondary elevation of KS can be caused by several factors including the release of KS from damaged bone and cartilage. 58, 59, 61 However, newborn DBS from MPS I, II, or III subjects showed no elevation of KS at birth. 54 The elevated KS in AF surrounding the MPS VII fetus in this study could suggest a more severe phenotype, including skeletal damage and/or developmental impairment in utero.
CONCLUSION
In this first report of quantification of GAGs in AF surrounding an MPS VII fetus using liquid chromatography tandem mass spectrometry, we show that GAG elevation is present at 21 weeks of gestation. Thus, we suggest that GAG measurements in AF may become a valuable additional tool for the diagnosis of MPS VII and potentially other MPS types.
WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?
• Mucopolysaccharidosis VII (MPS VII; Sly Syndrome) is an autosomal recessive disorder caused by deficiency of β-glucuronidase, leading to accumulation of primary glycosaminoglycans (GAGs); • MPS VII has a broad clinical spectrum from the most severe lethal hydrops fetalis to attenuated forms with survival into adulthood despite somatic and cognitive impairment; • GAGs are elevated in a fetus with MPS VII.
WHAT DOES THIS STUDY ADD?
• Not only primary GAGs (HS, DS) but KS are accumulated as early as 21 weeks of gestation; • This is the first report of p.N379D substitution in GUSB; • Quantification of GAGs by mass spectrometry applies to prenatal diagnosis, prognosis, and screening for MPS. Enzyme activity in amniotic fluid supernatant (nmol/h/mL).
